BG
ETTX

Bollard Group’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History

Bollard Group’s Portfolio ETTX Stock Details ETTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,448
Closed -$3K – 302
2022
Q2 		$3K Hold
1,448
– – ﹤0.01% 278
2022
Q1 		$3K Hold
1,448
– – ﹤0.01% 421
2021
Q4 		$3K Hold
1,448
– – ﹤0.01% 430
2021
Q3 		$5K Hold
1,448
– – ﹤0.01% 415
2021
Q2 		$4K Hold
1,448
– – ﹤0.01% 416
2021
Q1 		$3K Hold
1,448
– – ﹤0.01% 425
2020
Q4 		$4K Hold
1,448
– – ﹤0.01% 420
2020
Q3 		$3K Sell
1,448
-4,571
-76% -$13K ﹤0.01% 425
2020
Q2 		$18K Buy
+6,019
New +$16.5K ﹤0.01% 415

Bollard Group's ETTX Position: Q3 2022 in Review

Bollard Group sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q3 2022, closing a stake of 1,448 shares — an estimated $3K sold.

Bollard Group first reported a position in ETTX in Q2 2020 and held it in 9 quarters. The position peaked at $18K in Q2 2020. 0 funds tracked by Wall St. Rank hold ETTX as of Q3 2022.

  • Bollard Group reported no remaining Entasis Therapeutics Holdings Inc. position as of Q3 2022 after selling out during the quarter.
  • Bollard Group sold 1,448 Entasis Therapeutics Holdings Inc. shares in Q3 2022, an estimated $3K.
  • Bollard Group first reported a position in Entasis Therapeutics Holdings Inc. in Q2 2020 and held it in 9 quarters.
  • Bollard Group's Entasis Therapeutics Holdings Inc. position peaked at $18K in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q3 2022.

Based on Bollard Group's 13F filing for Q3 2022, filed 9 Nov 2022.